Health Care & Life Sciences » Biotechnology | Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. | Ownership

Companies that own Alnylam Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
14,943,417
14.85%
14,611
0.19%
06/30/2018
Wellington Management Co. LLP
11,784,320
11.71%
2,181,158
0.27%
06/30/2018
The Vanguard Group, Inc.
7,456,188
7.41%
96,670
0.03%
06/30/2018
T. Rowe Price Associates, Inc.
5,213,963
5.18%
-7,355,371
0.09%
06/30/2018
Dodge & Cox
4,654,701
4.62%
-38,140
0.3%
06/30/2018
BlackRock Fund Advisors
4,650,987
4.62%
-47,980
0.03%
06/30/2018
Baillie Gifford & Co.
4,231,881
4.2%
397,668
0.32%
06/30/2018
SSgA Funds Management, Inc.
2,250,242
2.24%
118,425
0.02%
06/30/2018
Perceptive Advisors LLC
1,846,911
1.84%
566,109
5.16%
06/30/2018
Point72 Asset Management LP
1,356,408
1.35%
448,362
0.82%
06/30/2018

About Alnylam Pharmaceuticals

View Profile
Address
300 Third Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.alnylam.com
Updated 07/08/2019
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.